Cambridge Cognition Holdings PLC Partnership to tackle growing mental health need
07 June 2018 - 4:01PM
RNS Non-Regulatory
TIDMCOG
Cambridge Cognition Holdings PLC
07 June 2018
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Partnership to tackle growing mental health need
The digital neuroscience company Cambridge Cognition Holdings
plc (AIM: COG), which develops and markets digital solutions to
assess brain health, is pleased to announce a new strategic
collaboration and partnership with the University of Bristol to
accelerate the development of novel brain health products.
Mental and substance use disorders are now the leading cause of
disability worldwide, resulting in 23% of all years lost with a
global economic loss of a trillion US dollars every year(1) .
New scalable tools are needed to measure mental health
objectively and to enable clinicians to better diagnose and monitor
patients.
Cambridge Cognition's digital health products exemplify how new
technologies can transform clinical research and health, while the
team at the University of Bristol, led by Professor Marcus Munafò,
brings expertise in mental health and addiction along with an
established network of patient groups and clinicians.
The creation of this collaboration will enable the Company to
run in-patient studies with the University and accelerate the
development of new software applications to help clinicians address
the global need in mental health conditions.
Professor Marcus Munafò, Professor of Biological Psychology,
University of Bristol said: "This is an exciting opportunity to
rapidly translate our research into clinical practice and patient
benefit. We have worked with Cambridge Cognition for several years
and this partnership allows us to extend this work and build on
their experience of digital neuroscience."
Dr Jenny Barnett, Chief Scientific Officer, Cambridge Cognition
said: "We are delighted to extend and formalise our relationship
with the talented team at the University of Bristol. Working more
closely will enable us to build a pipeline of novel, evidence-based
and usable tools to better measure and monitor mental health across
all ages groups and accelerate our ability to validate our digital
health apps in a clinical setting."
Sources:
(1) World Health Organization (WHO) March 30, 2017
Enquiries
Cambridge Cognition Holdings PLC
Steven Powell, Chief Executive Officer Tel: 01223 810 700
Noah Konig, Director of Marketing press@camcog.com
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane (Corporate Broking)
Dowgate Capital Stockbrokers Limited (Joint Tel: 020 3903 7715
Broker)
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Graham Herring / Miles Nolan / Zach Cohen
About Cambridge Cognition
Cambridge Cognition is a digital neuroscience company developing
software products to better understand, detect and treat brain
health conditions. The company's cognitive technologies are used to
accelerate the research and development of new treatments, enhance
understanding of the brain and accurately assess cognitive health
in patients worldwide.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADMGGVKVFGRZM
(END) Dow Jones Newswires
June 07, 2018 02:01 ET (06:01 GMT)
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From Apr 2024 to May 2024
Cambridge Cognition (LSE:COG)
Historical Stock Chart
From May 2023 to May 2024